Learn more about how your automation vision will come to life
The coronavirus pandemic has driven much-needed innovation, particularly in diagnostic testing. For businesses, schools and other facilities to reopen safely, COVID-19 testing has become routine practice. As a result, labs are working overtime to conduct polymerase chain reaction (PCR) diagnostic testing to meet this increased demand.
Proteins, particularly antibodies, have tremendous research and clinical value, but growing and purifying them can be challenging. To isolate proteins of interest, and produce sufficient yields for ongoing study, labs must carefully remove genetic material, extraneous proteins and other molecules. The process is not unlike panning for gold.
High-throughput screening is a mainstay for cell line development. However, the complex instruments used for high-throughput methods have many moving parts, and automation is essential to streamline and accelerate the process. By minimizing human intervention, sophisticated software can simplify workflows, decrease errors and free up laboratory staff for other tasks.
Analytical Chemistry Lab in Cannabis Market Decreases Processing Times by 94% with Lab Automation Software
The cannabis industry is on track to exceed $40 billion in sales worldwide by 2024, according to Arcview Market Research and BDS Analytics. Countless medical benefits, easy-to-use applications and life-changing stories have helped derail old stereotypes and build respected legitimate businesses. With increasing social acceptance, variety and access, cannabis products are now evaluated like other ingestible items and expected to be safe for human consumption. Scientific testing and analysis have become an essential step in the industry’s economic chain. Testing labs are stepping up to provide reliable and repeatable testing procedures that cannabis companies can use to ensure product safety and credibility.
One in three adults worldwide has multiple chronic conditions. The Center for Disease Control predicts cancer cases will increase by 24% between2010 and 2020. Patient lives depend on new drug discoveries and continuous improvement of existing treatment options.